Format

Send to

Choose Destination
Med J Aust. 2005 Jun 20;182(12):607-8.

Tailoring access to high cost, genetically targeted drugs.

Abstract

Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.

PMID:
15963014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center